Worldwide Healthcare Trust PLC

Fund Information / Factsheet • Jun 21, 2021

Investment Objective

To invest in the global healthcare sector with the objective of achieving a high level of capital growth. In order to achieve its investment objective, the Company invests worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. It uses gearing, and derivative transactions to enhance returns and mitigate risk. Performance is measured against the MSCI World Health Care Index (net total return, sterling adjusted).

Five Year Performance (%)

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed; an investor may receive back less than the original amount invested.

Share Price (total return) +115.9%

Net Asset Value per share (total return) +96.1%

Benchmark: MSCI World Health Care Index (net total return; sterling adjusted) +78.9%

Source: Morningstar, Index - Bloomberg.

Ten Largest Holdings as at 31 May 2021

Name	Sector	Total
Bristol-Myers Squibb	North America	5.7
Merck & Co	North America	5.3
Boston Scientific	North America	5.1
AstraZeneca	Europe	4.6
Horizon Therapeutics	North America	3.8
UnitedHealth	North America	3.0
Vertex Pharmaceuticals	North America	3.0
AbbVie	North America	2.9
Natera	North America	2.8
Mirati Therapeutics	North America	2.8
Total		39.0

Portfolio Manager Trevor Polischuk

Portfolio Manager Sven H. Borho

Fast Facts	As at 31 May 2021
AIC Sector	Biotechnology & Healthcare
Launch Date & appointment April 1995 of Portfolio Manager
Annual Management Fee (payable by the Company): 0.65% of net assets plus 0.30% of market cap. up to £150m; in the range £150m to £500m 0.2%; in the range £500m to £1bn 0.15%; in the range £1bn to £1.5bn 0.125%; over £1.5bn 0.075% plus £57,500.
Performance Fee	See Annual Report for details
Ongoing Charges Ratio (OCR)*	0.9%
Continuation Vote	2024 AGM and every th AGM thereafter 5
Year / Half Year	31 March / 30 September
Capital Structure	65,039,755 shares

*Calculated at the financial year end, includes management fees and all other operating expenses, and excludes performance fees.

Trust Characteristics

84 Number of Holdings
Net Assets (£m)		2,372.3
Market Capitalisation (£m)		2,406.5
Dividends		Provisional payment dates: January & July
Indicative Yield		0.6%
Gearing		1.8%
Leverage**		Gross 110.2% Commitment 108.3%
Share Price (p)		3700.00
NAV(p) (cum income)		3647.47
Premium / (Discount)		1.4%
Portfolio Turnover p.a.		75.9%
Active Share***		73.6%

Sector, Geographical** & Asset Class*** Breakdown at 31 May 2021* (%)

Biotechnology	29.4	North America	68.2	Equities	86.6
Pharmaceutical	27.9	Emerging Markets	20.7	Equity Swaps	7.0
Healthcare Providers / Services	18.3	Europe	9.6	Unquoteds	6.4
Healthcare Equipment / Supplies	16.2	Asia	1.5	Total	100.0
Life Sciences Tools & Services	7.5	Total	100.0
Fixed / Variable Interest	0.5
Health Care Technology	0.2
Total	100.0

*Calculation based on economic exposure and expressed as a % of the total economic exposure. This includes all derivatives as an economically equivalent position in the underlying holding.

**Geographical analysis based on country of primary listing.

***Unquoted securities will not exceed 10% of the portfolio at the time of acquisition.

Source: All portfolio information sourced from Frostrow Capital LLP. Analysis excludes cash and cash equivalents, including liquidity funds.

Discrete Performance – Calendar Years (%)

Percentage Growth 12 Month Return	2016	2017	2018	2019	2020	YTD
NAV	5.2	16.5	-3.8	31.9	20.0	-0.8
Share Price	10.1	20.7	-5.0	32.3	19.9	-0.7
Index	11.2	9.4	8.8	18.4	10.3	2.5

Standardised Discrete Performance (%)

Percentage Growth 12 Month Return	May 16- May 17	May 17- May 18	May 18- May 19	May 19- May 20	May 20- May 21
NAV	23.2	11.1	-1.2	41.3	2.5
Share Price	34.7	10.6	-0.9	39.6	4.7
Index	21.4	3.1	10.8	26.3	2.2

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed. An investor may receive back less than the original amount invested.

Source: NAV (total return; fully diluted) & share price (total return) – Morningstar. Benchmark - Bloomberg.

** The Board has set the maximum leverage limit for both the Gross and the Commitment basis at 140% of the Company's Net Asset Value.

*** Active Share is expressed as a percentage and shows the extent to which a fund's holdings and their weightings differ from those of the fund's benchmark index. A fund that closely tracks its index might have a low Active Share of less than 20% and be considered passive, while a fund with an Active Share of 60% or higher is generally considered to be actively managed.

Codes
Sedol	0338530
ISIN	GB0003385308
Legal Entity Identifier (LEI)
	5493003YBCY4W1IMJU04
Global Intermediary
Identification Number (GIIN)
	FIZWRN.99999.SL.826
Bloomberg	WWH LN
EPIC	WWH

Investment Policy

The Company offers a superior UK-listed opportunity for capital appreciation through a diversified portfolio of worldwide pharmaceutical, biotechnology, healthcare equipment, and healthcare services companies. The Portfolio Manager seeks to reduce risk through extensive fundamental research, worldwide exposure, position limits, and balanced market capitalisations. The Company's investment policy allows gearing, through borrowing, of up to 20% of net assets and a net exposure to derivative investments (excluding swaps) of up to 5% of the portfolio. Equity swaps may also be used, counterparty exposure here is limited to 12% of the portfolio at the time of acquisition. Unquoted securities will not exceed 10% of the portfolio at the time of acquisition.

Discount / Premium Control Mechanism

The Directors have adopted an active discount management policy through the use of share buybacks, with a view to limiting the discount to the ex income NAV per share at which the shares trade to no more than 6%. Shares bought back may be held in treasury for reissue at later dates at not more than the discount at which they were purchased, and in any event at a discount no greater than 5% to the prevailing cum income net asset value per share. Any shares left in treasury are cancelled around the time of the AGM. In

Return vs Volatility (5 Years Annualised) – Chart (%)

Commentary

In May, the NAV per share was down 4.1%, the share price was down 2.8% and the MSCI World Health Care Index was down 0.6%.

The hallmark of 2021 – macro driven trading dynamics – continued yet again in May as the growth to value rotation carried on in earnest in the month. This was commensurate with large cap outperformance and small cap under performance. Broad market indices such as the S&P 500 and the MSCI maintained their all-time highs in dollar terms but were negative in the month in sterling terms.

May's broad market dynamics were evident in the Company's performance in the month. Underperformance due to allocation effect in emerging biotechnology stocks resulted in over 300 basis points loss of absolute and relative return. This phenomenon was also observed in the life science tools sector. One offset of import was allocation in emerging markets, which returned over 85 basis points of positive absolute and relative return.

These factors were very evident in the key individual contributors in May as the top two contributors (and three of the top four) were emerging market stocks, including Shanghai Kindly Medical Instruments Co., Ltd., Alphamab Oncology (Hong Kong), and Aier Hospital Group Co., Ltd. (China). The other top contributor in the month was AstraZeneca PLC. Shares outperformed after the company reported stellar first quarter results with industry leading top line growth despite difficult year-over-year comparisons due to pandemic dynamics.

Individual stocks that were notable detractors to performance were also a victim of the market wide rotation out of growth stocks into value stocks. Such was the case for Natera, Inc., the liquid biopsy company that sold off in the month despite a strong earnings report. Another diagnostics company, Gaurdant Health Inc., suffered a similar fate, exacerbated by investor disappointment over quarterly results. Finally, shares in Deciphera Pharmaceuticals Inc. fell lower after the company reported disappointing sales for their recently launched lead drug, Qinlock (ripretinib), for the treatment of late line gastrointestinal stromal tumors.

Looking ahead – once again – we hope for a return of investor interest on industry fundamentals as healthcare valuations continue to compress and look very compelling to us. We expect merger and acquisition activity, news flow about a permanent U.S. FDA commissioner, increased clarity on drug price reform, and positive clinical data for the sector could help turn around sentiment.

order to stop the share price trading at a significant premium to the NAV per share, the Company has the ability to issue new shares at a 0.7% premium to the cum income NAV per share.

How to Contact Us

Frostrow Capital LLP 25 Southampton Buildings London, WC2A 1AL

Tel.: 0203 008 4910 Fax: 0203 043 8889

Website: www.frostrow.com Email: info@frostrow.com

Risk Warnings

This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Before investing in the Company, or any other investment product, you should satisfy yourself as to its suitability and the risks involved, and you may wish to consult a financial adviser.

Any return you receive depends on future market performance and is uncertain. The Company does not seek any protection from future market performance so you could lose some or all of your investment. For information on the principal risks the Company is exposed to please refer to the Company's Annual Report or Investor Disclosure Document available at www.worldwidewh.com.

Shares in the Company are bought and sold on the London Stock Exchange. The price you pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company. Usually, at any given time, the price you pay for a share will be higher than the price you could sell it.

The Company has increased its exposure to investments via the use of an overdraft facility and derivatives, and this could potentially magnify any losses or gains made by the Company. The Annual Report and Investor Disclosure Document, available on the Company's website, include further details on the use of, and exposure to, derivatives.

Important Information

Worldwide Healthcare Trust PLC (the Company) is a public limited company whose shares are premium listed on the London Stock Exchange (LSE) and is registered with HMRC as an investment trust.

The Company has an indeterminate life, although shareholders consider and vote on the continuation of the Company every five years (the next such vote will be held in 2024).

This financial promotion is issued by Frostrow Capital LLP which is authorised and regulated by the Financial Conduct Authority ("FCA").

The MSCI information (relating to the Benchmark) may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation lost profits) or any other damages. (www.msci.com).